Astatine-211-labeled anti-CAIX antibody (girentuximab)

About Atonco

Atonco is a Paris-based, private biotech pioneering a disruptive approach in targeted alpha therapy (TAT) using Astatine-211. The company holds exclusive worldwide licenses for a proprietary antibody and radiolabeling technology, positioning it in the growing field of radiopharmaceuticals. Its lead program targets non-muscle invasive bladder cancer refractory to standard treatments, aiming to provide a novel intravesical therapy that could delay or prevent radical cystectomy. As a pre-revenue, clinical-stage company, Atonco's success hinges on clinical validation of its platform and navigating the complex manufacturing and regulatory pathway for alpha-emitting therapeutics.

Therapeutic Areas